<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2588-0519-2019-10066</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-440</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕГИСТРЫ ПАЦИЕНТОВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REGISTERS PATIENTS</subject></subj-group></article-categories><title-group><article-title>Анализ антитромботической терапии фибрилляции предсердий в международных и российских регистрах</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3107-7636</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетько</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetko</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., профессор, зав. кафедрой фармакологии</p><p>Саратов</p></bio><bio xml:lang="en"><p>MD, professor, Head of Department of Pharmacology</p><p>Saratov</p></bio><email xlink:type="simple">reshetko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры фармакологии</p><p>Саратов</p></bio><bio xml:lang="en"><p>postgraduate student of Department of Pharmacology</p><p>Saratov</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фурман</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Furman</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к. м. н., зав. отделом неотложной кардиологии НИИ кардиологии</p><p>Саратов</p></bio><bio xml:lang="en"><p>PhD, Head of Emergency Cardiology Department, ResearchInstitute of Cardiology</p><p>Saratov</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saratov Medical University named after V.I. Razumovsky</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>07</month><year>2019</year></pub-date><volume>0</volume><issue>1</issue><fpage>83</fpage><lpage>96</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Решетько О.В., Соколов А.В., Фурман Н.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Решетько О.В., Соколов А.В., Фурман Н.В.</copyright-holder><copyright-holder xml:lang="en">Reshetko O.V., Sokolov A.V., Furman N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/440">https://www.clinvest.ru/jour/article/view/440</self-uri><abstract><p>В статье рассмотрены особенности организации международных и российских регистров больных фибрилляцией предсердий (ФП), клинико-демографические характеристики пациентов, включённых в регистры, а также особенности антитромботической терапии ФП и её соответствие современным клиническим рекомендациям. В ряде крупных рандомизированных контролируемых исследований (РКИ) была доказана не меньшая эффективность, а в ряде случаев превосходство прямых оральных антикоагулянтов (ПОАК) над варфарином в профилактике ишемического инсульта у пациентов с неклапанной ФП при лучшем профиле безопасности и удобстве применения. Однако актуальной остаётся проблема применения полученных в ходе РКИ данных в реальной клинической практике, для решения которой большую популярность набирают медицинские регистры. В статье приводится анализ 16 проспективных многоцентровых международных и российских регистров пациентов с ФП. Для удобства сравнения регистры разделены на три группы в соответствии с особенностями организации и критериями включения. Сделаны однозначные выводы о несоответствии реальной клинической практики антитромботической терапии ФП современным клиническим рекомендациям. Выявлены отличия в популяции больных ФП в России по сравнению с европейскими странами, что позволило сделать вывод о недостаточном выявлении ФП на амбулаторном этапе диагностики и вытекающую из этого ненадлежащую антикоагулянтную терапию, направленную на профилактику инсульта и тромбоэмболических осложнений, которые могут быть обусловлены разницей в социально-экономическом статусе регионов и особенностями организации медицинской лечебно-профилактической помощи населению.</p></abstract><trans-abstract xml:lang="en"><p>In the article the features of the organization of international and Russian registers of patients with atrial fibrillation (AF), the clinical and demographic characteristics of patients included in the registers, as well as the features of antithrombotic therapy of AF and its compliance with current clinical guidelines were observed. In a number of large randomized controlled trials (RCTs), not less effectiveness, and in some cases, the superiority of direct oral anticoagulants (DOACs) over warfarin, were proved in the prevention of ischemic insulin stroke patients with non-valvular AF with better safety profile and ease of use. However, the problem of the use of data obtained during RCTs in real clinical practice, for the solution of which medical registers are gaining much popularity, remains relevant. The article provides an analysis of 16 prospective multicenter international and Russian registers of patients with AF. For convenience of comparison, registers were divided into three groups in accordance with the features of the organization and inclusion criteria. Unambiguous conclusions were drawn about the incompatibility of the real clinical practice of antithrombotic therapy of AF with current clinical recommendations. Differences in the population of patients with AF in Russia compared with European countries were found, which led to the conclusion that insufficient detection of AF at the outpatient stage of diagnosis and the resulting inappropriate anticoagulant therapy aiming the prevention of stroke and ischemic complications take place, which may be due to the differences in the socioeconomic status of the regions and the characteristics of the organization of medical treatment and preventive care to the population.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>регистры</kwd><kwd>фибрилляция предсердий</kwd><kwd>антитромботическая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>registers</kwd><kwd>atrial fibrillation</kwd><kwd>antithrombotic therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrialfi brillation, strokerisk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103—8. DOI: 10.1161/STROKEAHA.113.002329.</mixed-citation><mixed-citation xml:lang="en">Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrialfi brillation, strokerisk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103—8. DOI: 10.1161/STROKEAHA.113.002329.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fi brillation. J Am Heart Assoc. 2015;21;4(1):e001486. DOI: 10.1161/JAHA.114.001486.</mixed-citation><mixed-citation xml:lang="en">Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fi brillation. J Am Heart Assoc. 2015;21;4(1):e001486. DOI: 10.1161/JAHA.114.001486.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;9(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fi brillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746—51. doi: 10.1093/eurheartj/eht280. Conen D Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323—1324. DOI: 10.1093/eurheartj/ehy171.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;9(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fi brillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28—34. DOI: 10.1016/j.ejim.2018.05.016.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;9(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fi brillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899—906. DOI: 10.1093/eurheartj/ehw658.</mixed-citation><mixed-citation xml:lang="en">Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fi brillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746—51. doi: 10.1093/eurheartj/eht280. Conen D Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323—1324. DOI: 10.1093/eurheartj/ehy171.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fi brillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975—2983. DOI: 10.1093/eurheartj/ehy411.</mixed-citation><mixed-citation xml:lang="en">Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fi brillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746—51. doi: 10.1093/eurheartj/eht280. Conen D Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323—1324. DOI: 10.1093/eurheartj/ehy171.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Camm AJ, Accetta G, Ambrosio G, et al for the GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fi brillation. Heart. 2017;103:307—314. http://dx.doi.org/10.1136/heartjnl-2016-309832.</mixed-citation><mixed-citation xml:lang="en">Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fi brillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28—34. DOI: 10.1016/j.ejim.2018.05.016.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Apenteng PN, Gao H, Hobbs FDR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fi brillation: fi ndings from the GARFIELD-AF registry. BMJOpen. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.</mixed-citation><mixed-citation xml:lang="en">Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fi brillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28—34. DOI: 10.1016/j.ejim.2018.05.016.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. European Heart Journal — Cardiovascular Pharmacotherapy. 2017;3:147—150, https://doi.org/10.1093/ehjcvp/pvx003.</mixed-citation><mixed-citation xml:lang="en">Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fi brillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899—906. DOI: 10.1093/eurheartj/ehw658.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология: Основы доказательной медицины. — М.: Медиа Сфера; 1998.</mixed-citation><mixed-citation xml:lang="en">Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fi brillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899—906. DOI: 10.1093/eurheartj/ehw658.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115(13):1819—22. DOI: 10.1161/CIRCULATIONAHA.106.618603.</mixed-citation><mixed-citation xml:lang="en">Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fi brillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975—2983. DOI: 10.1093/eurheartj/ehy411.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly SJ, Ezekowitz MD, Yusuf S, at al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139—51. DOI: 10.1056/NEJMoa0905561.</mixed-citation><mixed-citation xml:lang="en">Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fi brillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975—2983. DOI: 10.1093/eurheartj/ehy411.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011;365:981—992. DOI: 10.1056/NEJMoa1107039.</mixed-citation><mixed-citation xml:lang="en">Camm AJ, Accetta G, Ambrosio G, et al for the GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fi brillation. Heart. 2017;103:307—314. http://dx.doi.org/10.1136/heartjnl-2016-309832.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Patel MR, Mahaff ey KW, Garg J, Pan G, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365:883—891. DOI: 10.1161/CIRCULATIONAHA.</mixed-citation><mixed-citation xml:lang="en">Camm AJ, Accetta G, Ambrosio G, et al for the GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fi brillation. Heart. 2017;103:307—314. http://dx.doi.org/10.1136/heartjnl-2016-309832.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Apenteng PN, Gao H, Hobbs FDR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fi brillation: fi ndings from the GARFIELD-AF registry. BMJOpen. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fi brillation. Cochrane Database of Systematic Reviews. 2018 Mar 6;3:CD008980. DOI: 10.1002/14651858.CD008980.pub3.</mixed-citation><mixed-citation xml:lang="en">Apenteng PN, Gao H, Hobbs FDR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fi brillation: fi ndings from the GARFIELD-AF registry. BMJOpen. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yao X, Abraham NS, Alexander GC, et al. Eff ect ofAdherence to OralAnticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. DOI: 10.1161/JAHA.115.003074.</mixed-citation><mixed-citation xml:lang="en">Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. European Heart Journal — Cardiovascular Pharmacotherapy. 2017;3:147—150, https://doi.org/10.1093/ehjcvp/pvx003.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.</mixed-citation><mixed-citation xml:lang="en">Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. European Heart Journal — Cardiovascular Pharmacotherapy. 2017;3:147—150, https://doi.org/10.1093/ehjcvp/pvx003.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П. Рандомизированные клинические исследования и наблюдательные исследования: соотношение в иерархии доказательств эффективности лекарств // Рациональная фармакотерапия в кардиологии. — 2016. — Т.12. — №5. — С.567—573. DOI: 10.20996/1819-6446-2016-12-5-567-573.</mixed-citation><mixed-citation xml:lang="en">Fletchtr R, Fletcher C, Vagner E. Clinical epidemiology. Basics of the evidence-based medicine. Moscow: Media Sphere; 1998. (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fanaroff AC, Steff el J, Alexander JH, et al. Stroke prevention in atrial fi brillation: re-defi ning ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932—2941 https://doi.org/10.1093/eurheartj/ehy236.</mixed-citation><mixed-citation xml:lang="en">Fletchtr R, Fletcher C, Vagner E. Clinical epidemiology. Basics of the evidence-based medicine. Moscow: Media Sphere; 1998. (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fi brillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422—2434.</mixed-citation><mixed-citation xml:lang="en">Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115(13):1819—22. DOI: 10.1161/CIRCULATIONAHA.106.618603.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany — results from the German AFNET registry. BMC Neurol. 2015;5(15):129. DOI: 10.1186/s12883-015-0371-8.</mixed-citation><mixed-citation xml:lang="en">Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115(13):1819—22. DOI: 10.1161/CIRCULATIONAHA.106.618603.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Nabauer M, Gerth A, Limbourg T, et al. Th e Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Ezekowitz MD, Yusuf S, at al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139—51. DOI: 10.1056/NEJMoa0905561.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fi brillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. ClinCardio. 2014;37:277—284. doi: 10.1002/clc.22272.</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Ezekowitz MD, Yusuf S, at al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139—51. DOI: 10.1056/NEJMoa0905561.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fi brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9):1308—18. DOI: 10.1093/europace/euw073.</mixed-citation><mixed-citation xml:lang="en">Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011;365:981—992. DOI: 10.1056/NEJMoa1107039.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mazurek M, Huisman MV, Rothman KJ, et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017 Dec;117(12):2376—2388. DOI: 10.1160/TH17-08-0555.</mixed-citation><mixed-citation xml:lang="en">Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011;365:981—992. DOI: 10.1056/NEJMoa1107039.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fi brillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606—612.</mixed-citation><mixed-citation xml:lang="en">Patel MR, Mahaff ey KW, Garg J, Pan G, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365:883—891. DOI: 10.1161/CIRCULATIONAHA.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.</mixed-citation><mixed-citation xml:lang="en">Patel MR, Mahaff ey KW, Garg J, Pan G, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365:883—891. DOI: 10.1161/CIRCULATIONAHA.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.</mixed-citation><mixed-citation xml:lang="en">Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fi brillation. Cochrane Database of Systematic Reviews. 2018 Mar 6;3:CD008980. DOI: 10.1002/14651858.CD008980.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.</mixed-citation><mixed-citation xml:lang="en">Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fi brillation. Cochrane Database of Systematic Reviews. 2018 Mar 6;3:CD008980. DOI: 10.1002/14651858.CD008980.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Лукьянов М.М., Бойцов С.А., Якушин С.С. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА) // Рациональная Фармакотерапия в Кардиологии. — 2014. — Т.10. — №4. — С.366—77. https://doi.org/10.15829/1728-8800-2014-6-3-8.</mixed-citation><mixed-citation xml:lang="en">Yao X, Abraham NS, Alexander GC, et al. Eff ect ofAdherence to OralAnticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. DOI: 10.1161/JAHA.115.003074.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Степина Е.В., Лукьянов М.М., Бичурина М.А., и др. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью на госпитальном и амбулаторном этапах лечения по данным регистра РЕКВАЗА-КЛИНИКА // Рациональная Фармакотерапия в Кардиологии. — 2017. — Т.13. — №2.— С.146—154. https://doi.org/10.15829/1728-8800-2017-2-33-38.</mixed-citation><mixed-citation xml:lang="en">Yao X, Abraham NS, Alexander GC, et al. Eff ect ofAdherence to OralAnticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. DOI: 10.1161/JAHA.115.003074.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Михин В.П., Масленникова Ю.В., Лукьянов М.М. Структура госпитализации и антитромботическая терапия у больных фибрилляцией предсердий в сочетании с ишемической болезнью сердца (данные регистра РЕКВАЗА ФП-Курск) // Архивъ внутренней медицины. — 2017. — Т.7. — №3. — С.217—223</mixed-citation><mixed-citation xml:lang="en">Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Якусевич В.В., Позднякова Е.М., Якусевич В.В., и др. Амбулаторный пациент с фибрилляцией предсердий: основные характеристики. Первые данные регистра РЕКВАЗА ФП — Ярославль // Рациональная Фармакотерапия в Кардиологии. — 2015. — Т.11. — №2. — С.149—152. https://doi.org/10.20996/1819-6446-2015-11-2-149-152.</mixed-citation><mixed-citation xml:lang="en">Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П., и др. Опыт изучения фибрилляции предсердий на базе регистра ПРОФИЛЬ // Кардиоваскулярная терапия и профилактика. — 2014. — Т.13.— №2. — С.35—39. https://doi.org/10.15829/1728-8800-2014-2-35-39.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Effi cacy of Drugs. Racionalʹnaâ Farmakoterapiâ v Kardiologii. 2016; 12(5):567—573. (In Russ).DOI:10.20996/1819-6446-2016-12-5-567-573.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Кореннова О.Ю., Мальцев С.Н., Петренко А.В., Булахова Е.Ю. Фибрилляция предсердий в реальной клинической практике: уроки одного регионального регистра // Трудный пациент. — 2015. — Т.3. — №4. — С. 8—11.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Effi cacy of Drugs. Racionalʹnaâ Farmakoterapiâ v Kardiologii. 2016; 12(5):567—573. (In Russ).DOI:10.20996/1819-6446-2016-12-5-567-573.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда). Оценка лекарственной терапии. Часть 1. Как лечатся больные перед инфарктом миокарда и как это влияет на смертность в стационаре // Рациональная фармакотерапия в кардиологии — 2012. — Т.8. — №5. — С.681—84.</mixed-citation><mixed-citation xml:lang="en">Fanaroff AC, Steff el J, Alexander JH, et al. Stroke prevention in atrial fi brillation: re-defi ning ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932—2941 https://doi.org/10.1093/eurheartj/ehy236.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Суворов А.Ю., и др. Характеристика пациентов с мозговым инсультом или транзиторной ишемической атакой, включенных в регистр ЛИС-2 (Люберецкое исследование смертности больных, перенесших мозговой инсульт). Рациональная Фармакотерапия в Кардиологии. — 2015. — Т.11. — №1. — С.18—24. https://doi.org/10.20996/1819-6446-2015-11-1-18-24.</mixed-citation><mixed-citation xml:lang="en">Fanaroff AC, Steff el J, Alexander JH, et al. Stroke prevention in atrial fi brillation: re-defi ning ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932—2941 https://doi.org/10.1093/eurheartj/ehy236.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е.В., Ежов А.В., Зенин С.А. и др. Клинический портрет пациента с фибрилляцией предсердий в Российской Федерации. Данные глобального регистра GLORIA AF // Российский кардиологический журнал. — 2017. — Т.9. — №149. — С.21—27. http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.</mixed-citation><mixed-citation xml:lang="en">Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fi brillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422—2434.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.</mixed-citation><mixed-citation xml:lang="en">Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fi brillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422—2434.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.</mixed-citation><mixed-citation xml:lang="en">Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany — results from the German AFNET registry. BMC Neurol. 2015;5(15):129. DOI: 10.1186/s12883-015-0371-8.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966</mixed-citation><mixed-citation xml:lang="en">Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany — results from the German AFNET registry. BMC Neurol. 2015;5(15):129. DOI: 10.1186/s12883-015-0371-8.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Якушин C.С., Марцевич С.Ю. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты // Рациональная фармакотерапия в кардиологии. — 2013. — Т.9. — №1.— С.4—14 https://doi.org/10.15829/1728-8800-2015-1-53-62.</mixed-citation><mixed-citation xml:lang="en">Nabauer M, Gerth A, Limbourg T, et al. Th e Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Гайсенок О.В., Леонов А.С. Применение пероральных антикоагулянтов у пациентов с фибрилляцией предсердий: данные когортного исследования // Рациональная фармакотерапия в кардиологии. — 2016.— Т.12. — №4. — С.376—379. DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.</mixed-citation><mixed-citation xml:lang="en">Nabauer M, Gerth A, Limbourg T, et al. Th e Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Самородская И.В., Третьяков В.В. Градиент смертности населения в возрасте 40—59 лет в субъектах Российской Федерации // Вестник РАМН. — 2014. — №7—8. — С.106—111. URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fi brillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. ClinCardio. 2014;37:277—284. doi: 10.1002/clc.22272.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Погосова Н.В., Оганов Р.Г., Суворов С.В. Почему в Москве смертность от сердечно-сосудистых заболеваний ниже, чем в других регионах Российской Федерации? // Кардиоваскулярная терапия и профилактика. — 2015. — Т.14. — №2. — С.4—12. DOI:10.15829/1728-8800-2015-2-4-12.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fi brillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. ClinCardio. 2014;37:277—284. doi: 10.1002/clc.22272.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.</mixed-citation><mixed-citation xml:lang="en">Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fi brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9):1308—18. DOI: 10.1093/europace/euw073.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fi brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9):1308—18. DOI: 10.1093/europace/euw073.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.</mixed-citation><mixed-citation xml:lang="en">Mazurek M, Huisman MV, Rothman KJ, et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017 Dec;117(12):2376—2388. DOI: 10.1160/TH17-08-0555.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.</mixed-citation><mixed-citation xml:lang="en">Mazurek M, Huisman MV, Rothman KJ, et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017 Dec;117(12):2376—2388. DOI: 10.1160/TH17-08-0555.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов А.А., Клейменова Е.Б., Сычев Д.А., и др. Анализ соблюдения клинических рекомендаций по антикоагулянтной терапии у пациентов стационара // Рациональная Фармакотерапия в Кардиологии — 2018. — Т.14 — №4. — С.501—508. DOI: 10.20996/1819-6446-2018-14-4-501-508</mixed-citation><mixed-citation xml:lang="en">Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fi brillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606—612.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&amp;-surveys/Observational-research-programme/atrialfibrillation-3-registry.management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.</mixed-citation><mixed-citation xml:lang="en">Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fi brillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606—612.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.</mixed-citation><mixed-citation xml:lang="en">Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.</mixed-citation><mixed-citation xml:lang="en">Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.</mixed-citation><mixed-citation xml:lang="en">Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.</mixed-citation><mixed-citation xml:lang="en">Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.</mixed-citation><mixed-citation xml:lang="en">Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.</mixed-citation><mixed-citation xml:lang="en">Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.</mixed-citation><mixed-citation xml:lang="en">Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.</mixed-citation><mixed-citation xml:lang="en">Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.</mixed-citation><mixed-citation xml:lang="en">Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.</mixed-citation><mixed-citation xml:lang="en">Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.</mixed-citation><mixed-citation xml:lang="en">Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.</mixed-citation><mixed-citation xml:lang="en">Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.</mixed-citation><mixed-citation xml:lang="en">Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.</mixed-citation><mixed-citation xml:lang="en">Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.</mixed-citation><mixed-citation xml:lang="en">Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.</mixed-citation><mixed-citation xml:lang="en">Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.</mixed-citation><mixed-citation xml:lang="en">Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.</mixed-citation><mixed-citation xml:lang="en">Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966</mixed-citation><mixed-citation xml:lang="en">Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966</mixed-citation><mixed-citation xml:lang="en">Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.</mixed-citation><mixed-citation xml:lang="en">Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.</mixed-citation><mixed-citation xml:lang="en">Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.</mixed-citation><mixed-citation xml:lang="en">Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.</mixed-citation><mixed-citation xml:lang="en">Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.</mixed-citation><mixed-citation xml:lang="en">Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.</mixed-citation><mixed-citation xml:lang="en">Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.</mixed-citation><mixed-citation xml:lang="en">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.</mixed-citation><mixed-citation xml:lang="en">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.</mixed-citation><mixed-citation xml:lang="en">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.</mixed-citation><mixed-citation xml:lang="en">Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508</mixed-citation><mixed-citation xml:lang="en">Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508</mixed-citation><mixed-citation xml:lang="en">Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&amp;-surveys/Observational-research-programme/atrialfibrillation-3-registry.</mixed-citation><mixed-citation xml:lang="en">escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&amp;-surveys/Observational-research-programme/atrialfibrillation-3-registry.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&amp;-surveys/Observational-research-programme/atrialfibrillation-3-registry.</mixed-citation><mixed-citation xml:lang="en">escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&amp;-surveys/Observational-research-programme/atrialfibrillation-3-registry.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
